Opportunity Information: Apply for RFA AA 09 008
Apply for RFA AA 09 008
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Alcohol Pharmacotherapy and the Treatment and Prevention of HIV/AIDS (R03)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.273 Alcohol Research Programs.
- This funding opportunity was created on Feb 12, 2009 and posted on Feb 12, 2009.
- Applicants must submit their applications by Apr 16, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $1,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Special district governments Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal governments (Federally recognized) City or township governments For profit organizations other than small businesses Public housing authorities/Indian housing authorities County governments Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This funding opportunity, titled "Alcohol Pharmacotherapy and the Treatment and Prevention of HIV/AIDS (R03)" (RFA AA 09 008), was issued by the National Institutes of Health through the National Institute on Alcohol Abuse and Alcoholism (NIAAA). It supports early stage, small scale research focused on alcohol use disorders (AUD) in people living with HIV, with a specific emphasis on testing whether medication based treatments for AUD are safe, workable, and practical in HIV affected settings. The core idea is to fund the kind of initial pilot work that can answer basic feasibility questions (for example, whether participants can be recruited and retained, whether the medication can be delivered as planned, whether the approach is acceptable in HIV care environments, and whether there are early signals of benefit or manageable side effects), so investigators are better positioned to compete for a larger follow on clinical study.
The purpose of the grant is narrowly defined around pharmacotherapies for alcohol problems in HIV infected populations. NIAAA is looking for "initial studies of the safety and feasibility" of using medications to treat alcohol use disorders among people with HIV. These pilot projects are expected to lay groundwork for later research that will more definitively test efficacy and effectiveness. The FOA highlights two broad future directions that these pilots should help enable. First, it points toward later trials of innovative single medication approaches or combined medication approaches for AUD in HIV populations, with downstream goals that matter directly to HIV outcomes: improving adherence to antiretroviral therapy, reducing viral mutation risk that can be driven by poor adherence, reducing toxicity or adverse effects related to alcohol and antiretroviral (ARV) interactions, and reducing sexual risk taking associated with alcohol use. Second, it encourages the field to examine whether AUD medications might also have prevention value by reducing alcohol driven risk behaviors in groups at high risk for transmitting or acquiring HIV, specifically noting gay men and minority women as priority populations for preventing secondary infections.
The award mechanism is the expanded R03 Research Project Grant, which is intended for small, self contained projects that can be completed relatively quickly with limited resources. The announcement explicitly frames these awards as pilot and feasibility studies and as a way to spur new collaborations between HIV/AIDS researchers and alcohol researchers. In other words, applicants are not expected to run large definitive clinical trials under this mechanism; they are expected to generate the preliminary data, operational experience, and collaborative infrastructure that would support a subsequent R01 level application. This FOA runs in parallel with an R01 announcement of identical scientific scope (RFA AA 09 007), which is meant for the larger efficacy and effectiveness studies that would typically follow successful pilot work.
In terms of funding scale and competitiveness, NIH anticipated a total pool of up to $1,000,000 for this R03 opportunity, with an expected 4 to 6 awards. No cost sharing or matching was required. The opportunity was categorized as discretionary grant funding in the health area, associated with CFDA 93.273 (Alcohol Research Programs). The posting and creation date were February 12, 2009, with an original and current closing date of April 16, 2009, and an archive date of May 17, 2009.
Eligibility was broad and included many types of organizations that commonly apply for NIH grants. Eligible applicants listed in the notice included public and private institutions of higher education, nonprofits (including those with and without 501(c)(3) status), for profit organizations (including small businesses), state and local governments (such as county, city, township, and special district governments), independent school districts, public housing authorities, Native American tribal governments (federally recognized) and other tribal organizations, and a range of additional categories such as faith based or community based organizations, historically Black colleges and universities (HBCUs), Hispanic serving institutions, Alaska Native and Native Hawaiian serving institutions, tribally controlled colleges and universities, U.S. territories or possessions, regional organizations, eligible federal agencies, and non U.S. entities (foreign organizations). Practically, this means the FOA was designed to attract both academic and community grounded research teams, including those able to work directly in HIV care settings or with populations at elevated HIV risk.
Overall, the grant opportunity can be summed up as a targeted push to develop and de risk medication based approaches for alcohol use disorders in the context of HIV treatment and prevention. It prioritizes early stage studies that address whether these approaches can be safely implemented and are feasible in real world HIV related populations and settings, while keeping a clear line of sight to later outcomes that matter to public health: stronger ARV adherence, fewer alcohol ARV complications, reduced sexual risk behavior, and reduced likelihood of onward HIV transmission in high risk groups.
Frequently Asked Questions (FAQs)
What is the title and identifier of this funding opportunity?
The opportunity is titled "Alcohol Pharmacotherapy and the Treatment and Prevention of HIV/AIDS (R03)" and is identified as RFA AA 09 008.
Which agency and institute issued this opportunity?
This funding opportunity was issued by the National Institutes of Health (NIH) through the National Institute on Alcohol Abuse and Alcoholism (NIAAA).
What is the main purpose of this grant?
The grant supports early stage, small scale research focused on alcohol use disorders (AUD) in people living with HIV, with an emphasis on initial studies that test whether medication-based treatments for AUD are safe and feasible in HIV-affected settings.
What type of research does this FOA prioritize?
It prioritizes pilot and feasibility studies of pharmacotherapies (medications) for alcohol problems in HIV-infected populations, especially studies that answer basic implementation questions such as recruitment, retention, deliverability, acceptability in HIV care environments, and early signals of benefit or manageable side effects.
Is this opportunity meant to fund large clinical trials?
No. The announcement frames these awards as pilot and feasibility studies. Applicants are not expected to run large, definitive clinical trials under the R03 mechanism. Instead, the goal is to generate preliminary data and operational experience to support later, larger studies.
What is the award mechanism for this funding opportunity?
The award mechanism is the expanded R03 Research Project Grant, designed for small, self-contained projects that can be completed relatively quickly with limited resources.
What is the “core idea” behind funding these pilot studies?
The core idea is to fund initial work that can de-risk and prepare investigators for a larger follow-on clinical study by answering feasibility questions (for example, whether participants can be recruited and retained and whether medication delivery is practical in HIV-related settings).
What kinds of feasibility questions are explicitly called out in the description?
Examples include whether participants can be recruited and retained, whether the medication can be delivered as planned, whether the approach is acceptable in HIV care environments, and whether there are early signals of benefit or manageable side effects.
How does this R03 relate to other NIH opportunities in the same area?
This FOA runs in parallel with an R01 announcement of identical scientific scope (RFA AA 09 007), which is intended for larger efficacy and effectiveness studies that would typically follow successful pilot work.
What future research directions is this FOA intended to enable?
The pilots are expected to lay groundwork for later research that more definitively tests efficacy and effectiveness. The description highlights later trials of innovative single-medication or combined-medication approaches for AUD in HIV populations, as well as research exploring prevention value by reducing alcohol-driven HIV risk behaviors in high-risk groups.
What downstream HIV-related outcomes are specifically mentioned?
The description points to outcomes such as improving adherence to antiretroviral therapy (ART), reducing viral mutation risk driven by poor adherence, reducing toxicity or adverse effects related to alcohol and antiretroviral (ARV) interactions, and reducing sexual risk-taking associated with alcohol use.
Does the FOA include an HIV prevention angle as well as treatment?
Yes. In addition to improving HIV treatment outcomes in people living with HIV, the FOA encourages examining whether AUD medications might reduce alcohol-driven risk behaviors in groups at high risk of transmitting or acquiring HIV, with the goal of preventing secondary infections.
Which prevention priority populations are explicitly named?
The description specifically notes gay men and minority women as priority populations for preventing secondary infections in the context of alcohol-driven risk behaviors.
What is the expected scale of funding and number of awards?
NIH anticipated a total pool of up to $1,000,000 for this R03 opportunity, with an expected 4 to 6 awards.
Is cost sharing or matching required?
No. The opportunity states that no cost sharing or matching is required.
How is this opportunity categorized?
It is categorized as discretionary grant funding in the health area and is associated with CFDA 93.273 (Alcohol Research Programs).
What are the key dates listed for this opportunity?
The posting/creation date is February 12, 2009. The original and current closing date is April 16, 2009. The archive date is May 17, 2009.
Who is eligible to apply?
Eligibility is broad and includes public and private institutions of higher education; nonprofits (with and without 501(c)(3) status); for-profit organizations (including small businesses); state and local governments; independent school districts; public housing authorities; Native American tribal governments (federally recognized) and other tribal organizations; faith-based or community-based organizations; HBCUs; Hispanic-serving institutions; Alaska Native and Native Hawaiian-serving institutions; tribally controlled colleges and universities; U.S. territories or possessions; regional organizations; eligible federal agencies; and non-U.S. entities (foreign organizations).
Are foreign (non-U.S.) organizations eligible to apply?
Yes. The eligibility list explicitly includes non-U.S. entities (foreign organizations).
Does this FOA encourage collaborations across research fields?
Yes. The announcement explicitly describes these awards as a way to spur new collaborations between HIV/AIDS researchers and alcohol researchers.
What is the overall focus of the opportunity in plain terms?
It is a targeted push to develop and de-risk medication-based approaches for alcohol use disorders in the context of HIV treatment and prevention, emphasizing early-stage studies that demonstrate safety and feasibility in real-world HIV-related populations and settings.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: OVC FY09 Training and Technical Assistance for Children s Justice Act Partnerships for Indian Grant Program
Previous opportunity: Alcohol Pharmacotherapy and the Treatment and Prevention of HIV/AIDS (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AA 09 008
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AA 09 008) also looked into and applied for these:
| Funding Opportunity |
|---|
| NHLBI Career Transition Award (K22) Apply for PAR 09 102 Funding Number: PAR 09 102 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Targeted Rural Health Research Grant Program Apply for HRSA 09 167 Funding Number: HRSA 09 167 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Drug Free Communities Mentoring Program Apply for SP 09 003 Funding Number: SP 09 003 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $75,000 |
| National Center for Construction Safety and Health (U60) Apply for RFA OH 09 001 Funding Number: RFA OH 09 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $5,000,000 |
| Grants to States for Loan Repayment Apply for HRSA 09 205 Funding Number: HRSA 09 205 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Initiative for Maximizing Student Development (IMSD) (R25) Apply for PAR 09 104 Funding Number: PAR 09 104 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Tools Technologies for Assessing Manual Therapies (SBIR R43/R44) Apply for RFA AT 09 003 Funding Number: RFA AT 09 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Womens Mental Health and Sex/Gender Differences Research (R01) Apply for PA 09 108 Funding Number: PA 09 108 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Womens Mental Health and Sex/Gender Differences Research (R21) Apply for PA 09 109 Funding Number: PA 09 109 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Translating Research to Protect Health through Health Promotion, Prevention, and Preparedness (R18) Apply for RFA CD 09 001 Funding Number: RFA CD 09 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $450,000 |
| AHRQ Research Infrastructure Program Phase II Limited Competition (R24) Apply for RFA HS 09 001 Funding Number: RFA HS 09 001 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $500,000 |
| Alzheimers Disease Core Centers (P30) Apply for RFA AG 10 001 Funding Number: RFA AG 10 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alzheimers Disease Research Centers (P50) Apply for RFA AG 10 002 Funding Number: RFA AG 10 002 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Services in Supportive Housing Apply for SM 09 007 Funding Number: SM 09 007 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $400,000 |
| Phase II Clinical Trials of Novel Therapies for Lung Diseases (U01) Apply for RFA HL 10 003 Funding Number: RFA HL 10 003 Agency: National Institutes of Health Category: Health Funding Amount: $800,000 |
| Developing Integrated Child Health Information Systems Promoting the use of Health Information Technology Apply for HRSA 09 180 Funding Number: HRSA 09 180 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Cooperative Agreements for State Sponsored Youth Suicide Prevention and Early Intervention Apply for SM 09 003 Funding Number: SM 09 003 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $500,000 |
| Public Health Research on Down syndrome (U01) Apply for RFA DD 09 005 Funding Number: RFA DD 09 005 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| Bangladesh HIV AIDS Follow on Activity Apply for USAID BANGLADESH 388 09 001 RFA Funding Number: USAID BANGLADESH 388 09 001 RFA Agency: Bangladesh USAID Dhaka Category: Health Funding Amount: $13,000,000 |
| NINDS Ischemic Stroke Genetics Consortium (U01) Apply for RFA NS 09 002 Funding Number: RFA NS 09 002 Agency: National Institutes of Health Category: Health Funding Amount: $900,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AA 09 008", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.